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Although the incidence of gastric cancer is declining, it remains the
second most common cause of cancer related deaths in the world.
The presence of advanced disease in the majority of patients with
gastric cancer and the limited therapeutic options are responsible
for the poor prognosis of patients suffering from gastric cancer
(Fuchs et al, 1995; Delchier et al, 1998). Recently, molecular
analysis has revealed the presence of various genetic and molecular
alterations which contribute to the process of gastric carcino-
genesis. Thus, activation of oncogenes, such as K-sam and c-met,
as well as the inactivation of tumour suppressor genes, such as p53,
have been reported to occur in gastric carcinoma (Wright et al,
1992; Tahara et al, 1996). Furthermore, alterations of adhesion
molecules, such as mutation of the E-cadherin gene, have been
reported in sporadic and familial gastric cancers (Tahara et al,
1996). Since histomorphological analysis has led to the hypothesis
that specific histological changes of the gastric mucosa precede the
development of gastric cancer, substantial efforts have been under-
taken to reveal the molecular alterations underlying the histological
changes, such as gastritis and intestinal metaplasia (Correa, 1992).
However, the exact sequence of genetic and molecular alterations
leading to the malignant transformation of the gastric mucosa
remain largely unknown. Case–control studies have shown that
family members of patients with gastric cancer have an increased
risk of developing gastric cancer, and epidemiological analysis has
revealed that the risk of developing gastric cancer is increased
approximately threefold in these families (Macklin, 1960; Boeing
et al, 1991; La Vecchia et al, 1992). Recently, Meining et al have
demonstrated increased cell proliferation in the gastric mucosa of
first-degree relatives of patients with gastric cancer irrespective of
Helicobacter pylori infection (Meining et al, 1998).
Three mammalian isoforms of transforming growth factor beta
(TGF-b) control the process of cell growth, cell differentiation,
migration and the formation of the extracellular matrix (Massague
et al, 1992). The biological activity of TGF-b1 is mediated through
binding to a heteromeric complex of TGF-b receptors I and II
(Massague et al, 1992; Kingsley, 1994). Recently, enhanced
expression of TGF-b1 has been reported in human gastric cancers
and TGF-b1 stimulates the fibrotic changes which occur in scir-
rhous gastric carcinoma (Mahara et al, 1994; Naef et al, 1997).
Thus, TGF-b1 exerts its transforming potential mainly through the
stimulation of stromal cells, angiogenesis and the suppression of
immune surveillance. In an effort to further analyse the role of
TGF-b1 in the process of gastric carcinogenesis, we assessed the
expression of TGF-b1 in gastric cancers and the tumour-free
gastric mucosa in patients with gastric cancer. Furthermore, in
order to assess the role of TGF-b1 in the process of gastric
carcinogenesis and its potential role in the progression of gastric
precancerous lesions, we studied the expression of TGF-b1 in the
gastric mucosa of first-degree relatives of patients with gastric
cancer and healthy volunteers.
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Summary Transforming growth factors beta (TGF-b) constitute a family of polypeptide growth factors that control cell growth, cell
differentiation and migration, as well as the formation of the extracellular matrix. Recent analyses revealed the overexpression of TGF-b1 in
human gastric cancers and demonstrated increased cell proliferation in the stomach of patients with gastric cancer and their first-degree
relatives. Using human gastric tissues obtained from patients with gastric cancer (n = 19), biopsies from healthy first-degree relatives of
gastric cancer patients (n = 18) and healthy individuals (n = 19), we analysed the expression of TGF-b1 using the reverse transcriptase
polymerase chain reaction (RT-PCR) and immunohistochemistry. Fifteen of 19 patients with gastric cancer expressed TGF-b1 in the tumour.
In 11 of these 15 cases TGF-b1 mRNA was also detectable in the non-tumourous stomach. Interestingly, all but two individuals with a first-
degree relative diagnosed with gastric cancer exhibited TGF-b1 expression in either the antrum or corpus biopsy or both. In contrast, only one
of 19 individuals without a family history of gastric cancer expressed TGF-b1 in the stomach (P < 0.0001). TGF-b1 expression is detectable in
a large proportion of gastric cancers and in the stomach of healthy first-degree relatives of gastric cancer patients. Since individuals without
gastric cancers in their family express TGF-b1 only in one of 19 cases, the induction of TGF-b1 expression in first-degree relatives of patients
with gastric cancer points to the presence of specific molecular alterations in a subgroup of individuals with an increased risk of developing
gastric cancer that may precede the development of gastric cancers. © 2000 Cancer Research Campaign
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The following products were purchased: Taq polymerase from
Gibco-BRL (Eggenstein, Germany). Oligonucleotides were
purchased from Invitek (Berlin, Germany). All other chemicals
and reagents were of molecular biology grade and were purchased
from Sigma Chemical (Deisenhofen, Germany).
Tissue samples
Normal and cancerous gastric tissue specimens were obtained
from 19 patients undergoing upper intestinal endoscopy or gastric
resection for gastric carcinoma. Ten males and nine females with a
mean age of 62 years (range 35–73 years) were enrolled in this
study. Biopsies were taken from the tumour and from the tumour-
free corpus and antrum in nine patients undergoing upper gastro-
intestinal endoscopy. In addition, a further group of patients
(n = 10) underwent gastric resection for gastric cancer. These
tissues were obtained from the tumour and from the tumour-free
gastric mucosa, which was located at least 8 cm from the margin
of the tumours. Immediately following surgical or endoscopical
removal all tissue samples were frozen in liquid nitrogen.
Furthermore, 18 individuals with a first-degree relative who had
undergone gastric resection for gastric cancer of the non-cardia
type were consecutively recruited at three centres for upper
gastrointestinal endoscopy. Four males and 14 females with a
mean age of 47 years (range 27–65 years) were enrolled in this
study. The patients’ characteristics and histological diagnosis are
given in Tables 1 and 4. Nineteen individuals with dyspeptic
symptoms were recruited as controls. Patients with a malignancy,
an active or a history of peptic ulcer, as well as a family history of
malignant disease were excluded from the control group. All indi-
viduals gave informed consent to be included in the study. All
studies were approved by the Human Subjects Committee of the
Medical Faculty of the University of Magdeburg.
Histological evaluation
Formalin-fixed biopsies were processed as previously described
and sections were stained with haematoxylin and eosin, and with
Warthin-Starry stain to detect H. pylori colonization. Grade and
activity of the gastritis were determined in accordance with the
Sydney system (Price, 1991). All histological assessments were
performed by a trained pathologist who was blinded to the diag-
nosis and family history of the patient.
RNA extraction
Total RNA was extracted from the human gastric tissue specimen
by the acid guanidinium-thiocyanate method as previously
described (Ebert et al, 1994).
Polymerase chain reaction
Oligonucleotide primers were purchased from Invitek (Berlin,
Germany). Primer sequences corresponding to human TGF-b1
mRNA were used for reverse transcriptase polymerase chain reac-
tion (RT-PCR) analysis (Stratagene, Amsterdam, The Netherlands).
b-Actin cDNA was amplified as previously described (Ebert et al,
1994) cDNAs were synthesized from total RNA (1 mg/sample)
isolated from the gastric tissues, using oligodeoxythymidylate and
reverse transcriptase (Ebert et al, 1994). Following inactivation,
1 ml of the reaction mixture was incubated in buffer containing
0.1 mM concentrations of dATP, dCTP, dGTP, dTTP, 0.2 mM
concentrations each of oligonucleotide primers, 50 mM magnesium
chloride (MgCl2) and a 10´ buffer consisting of 200 mM Tris–HCl
(pH 8.0), 500 mM potassium chloride (KCl), and 1 U Taq poly-
merase. Reaction cycles consisting of 1.5 min at 95°C, 0.8 min at
60°C and 0.3 min at 72°C were repeated 35 times for amplification
of human TGF-b1 (Massague et al, 1992; Kingsley, 1994). The
PCR products were size fractionated on 1.25% agarose gels and
visualized by ethidium bromide staining (Ebert et al, 1994). All
PCR amplifications were performed at least twice. cDNAs reverse
transcribed from mRNA extracted from mononucleate cells, were
used as positive control (not shown). In order to confirm the speci-
ficity of the cDNAfragments generated by RT-PCR, we performed
Southern blot analysis. The PCR fragments of five normal and five
tumourous gastric tissues were size fractionated on 1% agarose
gels, blotted on nylon membranes and hybridized by the method of
Southern (Ebert et al, 1994).
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Figure 1 RT-PCR analysis of TGF-b1 expression in gastric cancer and
normal gastric mucosa. Using cDNAs obtained from total RNA which had
been extracted from biopsies of gastric cancers and the tumour-free gastric
mucosa, a band corresponding to TGF-b1 was present in 15 of 19 gastric
cancers and in 16 of 18 gastric tissue specimens of first-degree relatives
from patients with gastric cancer. In contrast, healthy volunteers with no
family history of gastric cancer expressed TGF-b1 in only one case. (A) lanes
1–3: corpus, antrum, tumour biopsy of a patient with gastric cancer (Table 1,
No. 8); lanes 4–6: corpus, antrum, tumour biopsy of a patient with gastric
cancer (Table 1, No. 9); lanes 7–8: corpus and antrum biopsy of a first-
degree relative (Table 4, No. 9); lanes 9–10: corpus and antrum biopsy of
first-degree relative (Table 4, No. 10); lane 11: mononucleate cells serving as
a positive control; lane 12: negative control; lane 13: DNA ladder. (B) Lanes
1–3: corpus, antrum, tumour biopsy of a patient with gastric cancer (Table 1,
No. 6); lanes 4–7: normal control without a family history of gastric cancer;
lane 8: mononucleate cells serving as a positive control; lane 9: negative
control; lane 10: DNA ladder. Parallel PCR amplification of the cDNAs using
two primers specific for b-actin confirmed the integrity of the cDNAs usedImmunohistochemistry
A highly specific polyclonal antibody against human TGF-b1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) was utilized for
immunohistochemical analysis. The antibody was raised against an
epitope corresponding to an amino acid sequence mapping at the
carboxy terminus of the precursor form of human TGF-b1. This
antibody is specific for TGF-b1, with no cross-reactivity with TGF-
b2 or TGF-b3. Antibody specificity was confirmed by Western
blotting and immunoprecipitation studies (Muso et al, 1996).
Paraffin-embedded tissue sections from eight gastric cancers and
six non-malignant stomachs were subjected to immunostaining
using a streptavidin-peroxidase method. After blocking endogenous
peroxidase activity with 0.3% hydrogen peroxide in methanol, the
sections were incubated for 16 h with the anti-TGF-b1 antibody
(1:100). Bound antibody was detected with a biotinylated
IgG secondary antibody and streptavidin–peroxidase complex,
using diaminobenzidine tetrahydrochloride as the substrate.
Counterstaining was performed with Mayer’s haematoxylin (Ebert
et al, 1994).
Statistical analysis
All data were analysed using the c2 test, with P < 0.05 taken as the
level of significance (Siegel, 1956).
RESULTS
In the gastric mucosa of healthy controls TGF-b1 expression was
present only in one of 19 cases (Figure 1). In these 19 cases biop-
sies were obtained from the corpus and antrum of patients with
dyspeptic symptoms and histological analysis confirmed the diag-
nosis of gastritis in all cases. In contrast, 15 of 19 patients with
gastric cancer exhibited TGF-b1 expression in the tumour as deter-
mined by RT-PCR analysis (Table 1). Southern blot analysis of the
cDNA fragments encoding TGF-b1 confirmed the presence of
TGF-b1 in the cancer samples (Figure 2). Using a highly specific
anti-TGF-b1 antibody, TGF-b1 expression was observed in the
gastric cancer cells by immunohistochemical analysis (Figure 3).
The increased frequency of TGF-b1 in the gastric cancer tissues
(15/19) differs significantly from the data obtained from the
normal controls (P < 0.0001) (Table 2). In 14 of these 19 cancer
patients, TGF-b1 expression was also observed in the tissue
specimen obtained from the tumour-free stomach. Eleven cases
co-expressed TGF-b1 in the gastric cancer and the tumour-free
area (Table 1). However, in four cases TGF-b1 expression was
only observed in the gastric tumour, whereas in three cases TGF-
b1 was present in the tumour-free biopsy and was absent in the
tumour. Interestingly, all gastric cancers which did not express
TGF-b1 in the tumour were gastric cancers of the diffuse type
TGF-b1 in cancer relatives 1797
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Table 1 Patient characteristics and TGF-b1 expression in gastric cancer
No. Age Sex Hp TGF-b1 expression Histological type Lauren type
Tumour-free Tumour
1 65 F + – – Adenocarcinoma Diffuse
2 69 M + + – Adenocarcinoma Diffuse
3 71 M + + + Adenocarcinoma Intestinal
4 55 M + + + Signet ring cell Diffuse
5 60 F + + – Signet ring cell Diffuse
6 62 F – + + Adenocarcinoma Intestinal
7 73 M – – + Small cell
8 69 F + + + Adenocarcinoma Diffuse
9 37 M – + + Adenocarcinoma Intestinal
10 63 M – + + Adenocarcinoma Intestinal
11 69 M + + + Adenocarcinoma Diffuse
12 63 M + + + Adenocarcinoma Intestinal
13 69 M – + + Adenocarcinoma Intestinal
14 66 F – – + Signet ring cell Diffuse
15 35 M + + – Signet ring cell Diffuse
16 57 F + – + Signet ring cell Diffuse
17 64 F + + + Adenocarcinoma Intestinal
18 54 F + + + Adenocarcinoma Intestinal
19 63 F – – + Signet ring cell Diffuse





Figure 2 Southern blot analysis. The specificity of the cDNA fragments
corresponding to TGF-b1 was confirmed using Southern blot analysis as
described in Methods. In the normal gastric mucosa TGF-b1 expression was
not detected, however, in the gastric cancer tissues TGF-b1 was present as
determined by Southern blot analysis of cDNA fragments generated by RT-
PCR. All cases exhibited b-actin expression, confirming the integrity of the
cDNAs usedaccording to the Lauren classification, however, this finding did
not reach statistical significance (Table 3). Furthermore, neither
the histological type of gastric cancer, nor the status of H. pylori
infection correlated with TGF-b1 expression in gastric cancer
(Table 3).
In five patients with gastric cancer, a first-degree relative agreed
to undergo upper gastrointestinal endoscopy in order to exclude
gastric cancer and to determine the expression of TGF-b1 in biop-
sies obtained from the corpus and the antrum. Thirteen other indi-
viduals with a family history of gastric cancer were also studied.
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Table 3 Statistical analysis of TGF-b1 expression in gastric biopsies of




Tumour biopsy 15 4 1.00
Non-tumour biopsy 14 5
Adenocarcinoma 10 2 0.58
Signet cell cancer 4 2
Diffuse type 6 4 0.09
Intestinal type 8 0
Hp positive 8 4 0.24
Hp negative 7 0
First-degree relatives
Corpus 14 4 0.29
Antrum 10 8
No gastritis 3 1 1.00
Mild/moderate gastritis 21 11
With intestinal metaplasia 1 3 0.11
Without intestinal metaplasia 22 9
Hp positive 10 1 1.00
Hp negative 6 1
Table 4 Patients characteristics and TGF-b1 expression in gastric biopsies of first-degree relatives
No. Age Sex Hp Corpus Antrum Intestinal
Gastritis Gastritis
metaplasia
G A TGF-b1 G A TGF-b1
14 4 F+ 2 2 + 2 2 + –
24 2 F– 1 0 + 1 0 + –
3 4 2 F – 32 + 20– –
42 9 M + 1 1 + 2 2 + –
5 3 0 F – 00 + 00– –
6 3 8 M + 22 + 21– –
76 5 M + 2 2 + 2 2 + –
8 5 5 F + 22 + 32– +
96 0 F+ 2 2 + 2 2 + –
10 30 F – 2 2 – 1 0 – +
11 64 F + 1 1 – 2 2 + –
12 71 F + 1 1 + 2 2 + –
13 23 F + 2 2 + 3 2 – +
14 27 F – 1 0 + 1 0 + –
15 50 F + 3 2 – 3 3 + +
16 64 F – 0 0 + 0 0 + –
17 61 F + 2 1 – 3 2 – –
18 45 M – 1 1 + ND ND – –
F, female; M, male; –, negative; +, positive; ND, not determined; G, grade of gastritis; A, activity of gastritis; level of gastritis: 0, no gastritis; 1, minimal; 2,
moderate; 3, severe gastritis.
Table 2 Statistical analysis of TGF-b1 expression in gastric biopsies of
patients with gastric cancer and first-degree relatives versus normal controls
TGF-b1 expression P-value
+–
Gastric cancer 15 4 0.7085
First-degree relative 16 2
Gastric cancer 15 4 < 0.0001
Healthy individual 1 18
First-degree relative 16 2 < 0.0001
Healthy individual 1 18
Figure 3 Immunohistochemistry. Expression of TGF-b1 in gastric cancer
cells was detected by immunohistochemical analysis. Gastric cancers of the
intestinal type exhibited strong TGF-b1 immunoreactivity. Magnification: 400´We determined the expression of TGF-b1 in biopsies taken from
the corpus and the antrum of these 18 individuals (Table 4). All but
two of these 18 individuals exhibited TGF-b1 expression in either
the biopsy taken from the corpus or the antrum or in both biopsies,
a finding which contrasts with our results obtained from healthy
individuals (P < 0.0001; Tables 2 and 4). Eight first-degree rela-
tives co-expressed TGF-b1 in the corpus and antrum biopsy (Table
4). The presence of TGF-b1 in either the corpus or antrum biopsy
did not correlate with the grade of the gastritis, H. pylori infection
or the presence of intestinal metaplasia (Table 3).
DISCUSSION
The pathogenesis of gastric cancer remains largely unknown.
Epidemiological studies have revealed that H. pylori infection is
associated with gastric cancer and, thus, H. pylori was classified as
a group I carcinogen by the International Agency for Research on
Cancer in 1994 (Fuchs et al, 1995). Further analysis revealed that
H. pylori strains expressing the cagAgene may lead to more severe
inflammation and may be more common in patients with gastric
cancer. However, other studies could not find an association
between cagA status and gastric cancer (Delchier et al, 1998).
From histomorphological analysis a sequence of histological
changes has been described which may precede the development
of gastric cancer. Correa proposed that following atrophic gastritis,
intestinal metaplasia, dysplasia and eventually gastric carcinoma
may occur (Correa, 1992). However, the molecular alterations
underlying these histological changes are largely unknown. The
risk for the development of gastric cancer has been assessed using
different histological criteria. Whereas the presence of intestinal
metaplasia is still a matter of debate, other studies have shown that
a corpus-dominant inflammation along with intestinal metaplasia
in the antrum and corpus clearly defines a group of individuals
with an increased risk of developing gastric cancer (Scott et al,
1990; Miehlke et al, 1997).
Molecular analysis has identified a number of genetic and mole-
cular alterations which are present in gastric cancer. The activation
of oncogenes such as the rearrangement of TPR-MET, leading to
overexpression of the c-met protooncogene, as well as the amplifi-
cation of K-sam have been reported in gastric cancers. In contrast,
mutations of the K-ras oncogene are rare events in the process of
gastric carcinogenesis (Soman et al, 1990; Tahara et al, 1996).
Alteration of tumour suppressor genes such as MCC and APC
occur in approximately one-third of gastric cancers, whereas p53
gene mutations are present in the majority of gastric cancers
(Nakatsuru et al, 1993). Recently, alterations of mismatch repair
genes have been detected in gastric cancers. Ottini et al reported
that the replication error positive phenotype is present in 30% of
gastric cancers and that this phenotype is associated with an
advanced tumour stage, intestinal type, and antral location (Ottini
et al, 1997).
TGF-b1 binds to a heteromeric receptor complex of TGF-b
receptors I and II (Massague et al, 1992) and activates signalling
pathways which lead to the regulation of cell growth, cell differen-
tiation and the production of the extracellular matrix (Kingsley,
1994). Various studies have shown that TGF-b1 is overexpressed
in epithelial cancers and also in the stromal tissues surrounding the
cancer cells. Among others, brain tumours, thyroid cancers and
pancreatic cancers overexpress TGF-b1 in the tumour and the
overexpression of this growth factor is associated with a poor
survival in subgroups of these patients (Friess et al, 1993).
Enhanced expression of TGF-b1 has also been reported in gastric
cancers and in the fibrosis associated with scirrhous gastric carci-
noma (Mahara et al, 1994; Naef et al, 1997). Furthermore, the
expression of TGF-b1 in advanced gastric cancers is also associ-
ated with a shorter survival of these patients (Nakamura et al,
1998). The mechanism of TGF-b1 function in these cancers is
believed to be mediated primarily by the stimulation of the extra-
cellular matrix and suppression of an adequate immunological
response. Recently, our group and others have demonstrated the
induction of other growth factors in cancer cells by TGF-b1 which
may be derived from the cancer cells or the surrounding stromal
cells, pointing to autocrine and paracrine loops which give these
cancer cells an additional growth advantage (Ebert et al, 1995). In
our study, the expression of TGF-b1 in gastric cancers was
assessed using both RT-PCR analysis and immunohistochemistry.
For RT-PCR analysis, we used specific primers corresponding
to TGF-b1 mRNA and performed RT-PCR analysis with tissue
samples obtained during upper gastrointestinal endoscopy in
patients with gastric cancer. We also used gastric tissues obtained
from patients undergoing gastric surgery for gastric carcinoma.
Tissues were obtained from the tumour itself and a tumour-free
location. Our analysis demonstrates the expression of TGF-b1 in
the vast majority of gastric cancers. The expression of TGF-b1 in
the gastric cancer cells was confirmed by our immunohistochem-
ical analysis. Only four tumours did not express TGF-b1 in the
gastric tumour and all of these were of the diffuse type according
to the Lauren classification. TGF-b1 was also detected in the
tumour-free gastric mucosa in 14 of the 19 patients with gastric
cancer. Since a few cancers did not exhibit TGF-b1 expression in
the tumour, but expressed TGF-b1 in the tumour-free biopsy, we
assume that the expression of TGF-b1 in these areas may result
from the presence of inflammation in the tumour-free mucosa in
these cases. The presence of TGF-b1 in either the tumour or the
tumour-free tissue did not correlate with H. pylori infection, an
observation which points to the presence of molecular mechanisms
in gastric cancer which are independent of H. pylori and indicates
that the role of H. pylori in gastric carcinogenesis may be rather
confined to the induction of gastric inflammation.
Identifying individuals with an increased risk of developing
cancers and the correct clinical management and follow-up of
these individuals is a challenge for clinicians. Epidemiological
studies have shown that first-degree relatives of patients with
gastric cancer may have an increased risk of developing gastric
cancer (Macklin, 1960; Boeing et al, 1991; La Vecchia et al, 1992).
However, the genetic and molecular alterations underlying this
increased risk remain largely unknown. Recently, increased cell
proliferation in the gastric mucosa of individuals with a family
history of gastric cancer has been demonstrated (Meining et al,
1998). This increase in cell proliferation was independent of H.
pylori infection. The results of this study further support the
hypothesis that not only environmental conditions, but most
importantly, also genetic and molecular alterations contribute to
the development of gastric cancer in first-degree relatives. We
demonstrate a high frequency of TGF-b1 expression in gastric
cancers and in the gastric mucosa of first-degree relatives, a
finding which contrasts sharply with our data from healthy
controls. Since TGF-b1 may mediate its transforming potential by
indirect means, the presence of TGF-b1 in the gastric mucosa of
first-degree relatives with an increased risk of developing gastric
TGF-b1 in cancer relatives 1799
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individuals which in turn may contribute to the progression of
premalignant lesions in these individuals. In summary, our obser-
vations point to the presence of molecular alterations in the
stomach of first-degree relatives which may precede the develop-
ment of gastric cancers in this subgroup of individuals.
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